Skip to content
Reengineering Drug Discovery and Development episode artwork

Sep 4, 2014 21 min

Reengineering Drug Discovery and Development

from The Bio Report Hosted by Levine Media Group

Drugmakers have employed new technologies to reduce the cost and time and it takes develop drugs and produce therapies that more precisely target the underlying biology driving diseases. Boston-based Berg Pharma is using artificial intelligence with a variety of other technologies to reengineer the discovery and development process. We spoke to Niven Narain, co-founder, president, and chief technology officer of Berg, about the problems with drug development today, what makes his company's approach unique, and what its pipeline can tell us about whether the approach is working.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Reengineering Drug Discovery and Development

0:00 21:02

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 21 minutes long.

When was this The Bio Report episode published?

This episode was published on September 4, 2014.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.